Get started

Shortsqueeze

Retest time?Seems like levels are close to the halfway mark in the Fib retracement. We're looking at a 27% rally from the low. Not sure why the rally has lasted this long and been so strong, it could be from a short squeeze...who knows. It has to end soon I would imagine. We are heading into earnings with bad news ahead of us plus more bad economic news, so I anticipate the move down is coming soon. I just can't believe the market has completely priced everything in yet. Prove me wrong.
CME_MINI:ES1!Short
by napatrader
1
Short squeeze in play for BitcoinWhy would Bitcoin pump when everyone is convinced it is going to fall further? The answer is simple: when people expect Bitcoin to fall further, they place Short orders that can be liquidated if Bitcoin price rises to a certain level. When Short order hits a stop-loss or and gets liquidated, it is done so by placing a market Buy order, which lifts the price up. Usually traders place their stop orders slightly above the previous high, which provides them with confidence. However, smart whales are aware of these stops and they know that when they move the price to a certain point, it will trigger stop-losses and will add more buying pressure. This is what we saw in play back on October 2019, and it can also be seen on lower time-frame today. Today’s surge is not due to the fact that Bitcoin has a good Long set-up, rather it had such an obvious Short set-up that it was seductive to liquidate all small traders and profit from the buying pressure which resulted from liquidation. Be careful with Bitcoin , this is a huge game of speculation, and price is the most important variable here.
BITSTAMP:BTCUSD
by VovaNapas
5
EU: Potential Short SqueezeCould the USD lose some momentum with preliminary job-loss claims coming? Expected to see up to 2 million people claiming unemployment for March... The FEDs last move to introduce unlimited QE and buying of corporate bonds could be showing a limited affect.. A short-squeeze could be coming - acting as a retracement for the drop that occurred from 1.1500 I entered long at 1.07750 - looking to take profit at or around 1.10650 -First level for bulls to break at 1.08100 I keep a pretty tight stop, so if price breaks and closes below 1.07700 I'll close position and continue short trend. *trade at own risk -Krecioch
Long
by Krecioch
3
Bullish on AMC stockBears have dramatically discounted this already over-discounted stock... Honestly I'd definitely look to buy anything below $4.60 (if you can!). I don't see these prices lasting long. As with any stock that is bottoming, don't go all in thinking it's at a bottom and then panic sell because it drops (or goes up) 10 or 20 cents. That is exactly what caused this to keep dropping in the first place! You want to see a bottom form and a fast (or steady) move upward. Then wait for the dip and start buying at the support level or just above/below.
NYSE:AMC
by KingHammer_
CRSP LONG breakout potentialCRSP got some attention a few months ago with the Netflix series "Unnatural Selection" in which it melted up for a while before crashing down on profit taking As CRSP broke its minor downward trendline and came back down to a retest, a long position with a good reward to risk ratio can be entered with a tight stop. Factors leading to the decision: The recent downtrend has been broken after price recently bounced at a major support line The 20ma was broken, pulling in moving-average traders off the side-lines A recent low offers a perfect spot to put a logical technical stop Price is now finishing a retracement after bouncing off recent highs, so we can avoid that pain by entering now that the retracement seems to be flattenting out As always, respect a tight-stop. If it rips up, let it run and trail stops behind.
NASDAQ:CRSPLong
by ericsolan
BTC Giant bull trapTo me 3 things are obvious: 1. The latest BTC spike is abnormal. It occurred for no apparent reason and coincided with bitfinex maintenance. 2. The spike came at a time when bulls are losing steam and someone could argue that it looks like a BIG FLASHING NEON SIGN urging them to re-enter the race. 3. Nothing defies nature's laws, and what goes up will come down. Conclusion: "What you don't know, won't hurt you, it'll kill you. Like if they tell you you're going to shower but they turn out not to be showers." and since it seems that I do not know a lot about the recent events I decide to stay out of the market until things start to make any sense.
COINBASE:BTCUSDLong
by fpunx
11
Is Beyond Meat Roasting the Bears?The bulls and the bears have taken their turns feasting on plant-based food maker Beyond Meat . First the bulls, then the bears … and now the bulls may be back. BYND initially flew higher after its May 2019 IPO, ripping from $25 to over $220. It then fizzled out and crashed all the way back down into the $70s. Buyers came back with an appetite in 2020 and drove it back over $100. The heavily-shorted stock soon formed a bullish flag and volatility began to fade. Back-to-back inside days occurred on February 5 and 6. That signaled its wild swings were calming down. Technicians watch for this kind of pattern because breakouts usually follow price contractions. Since the initial move was higher, it created an opportunity for classic trend following to the upside. The confirmation came the next session with a high-volume candle and BYND's highest close in February. That put some pressure on the bears and started squeezing the shares higher. Now they've got about two months until earnings to sweat it out.
NASDAQ:BYNDLong
by TradeStation
1
$IRBT Expect A Short SqueezeYesterday we got the catalyst we were looking for from $IRBT - a solid earnings report. With 48% of the float short, we expect $IRBT to squeeze the shorts. Here are the highlights" iRobot (NASDAQ:IRBT): Q4 Non-GAAP EPS of $0.69 in-line; GAAP EPS of $0.70 beats by $0.29. Revenue of $426.78M (+10.9% Y/Y) beats by $10.83M. Shares of iRobot (NASDAQ:IRBT) popped after the company hires a new CFO and reports Q4 EPS even above the highest estimate turned in by analysts. Revenue was up 11% during the quarter and operating income came in at $16.6M vs. $29.8M a year ago. Tariff costs factored into the OI decline. The company promoted VP of finance Julie Zeiler to take over the CFO position from Alison Dean. As always, trade with caution and use protective stops. Good luck to all!
NASDAQ:IRBTLong
by InsiderFinancial
BTC- Rise- pullback- liftoffAlmost two months into the uptrend and,it seems that BTC is well into the green zone judging from the weekly timeframe. Bitmex OI just hits 10 figures, but I want to see a little bit more volume. Binance OI is rising steadily and long consistently hovers above 50% the past 30 days. We can assume the rise of OI coincides with the rising bullish sentiment. Overall, volume is rising steadily across all exchanges over the past 30 days which validates the uptrend movement. Ongoing shorts liquidation at the time of this writing... I think BTC is due for another pullback to sub 9k area or it may attack 9.8k- 10.3k region, then retraces back to between 8.6k to sub 9k. Mid -term outlook looks bright for BTC :)
Long
by Libratus
2
$MNK A Buy On 56% Of The Float Short$MNK is up 40% this week after positive comments from the company's CFO. With a massive short position in the stock, we think this rally has further room to run. The stock started rallying this week after Chief Financial Officer Bryan Reasons said at the J.P. Morgan Health Care Conference on Monday that the company could pay off its potential 2020 debt maturities, which is a "slightly over" $600 million, in cash. And regarding the dispute with the government over pricing for Acthar, he implied that he was optimistic regarding a favorable outcome, so there was no need to rush to settle. "Right now, we felt like the hearing went really well and we feel good about it," Reasons said, according to a transcript provided by FactSet. "So, we don't feel it's in our best interest to actually initiate the settlements." And regarding the opioid litigations, Chief Executive Mark Trudeau said he was "hopeful" that a resolution can be reached "sooner rather than later." The stock has more than doubled (up 110%) over the past three months, but is still way down 83% off its 52 week high of $27.33 a share. As always, use protective stops and trade with caution. Good luck to all!
M
by InsiderFinancial
$JMIA Going To Squeeze The Shorts With 82% Of Float Short$JMIA is on the verge of an epic short squeeze. While the shorts have been right on the money so far, we believe they have overstayed their welcome and are going to be forced to cover. Yesterday's news: Jumia (NYSE:JMIA) has named Kenneth Oyolla as its new chief commercial officer, replacing Diana Owusu-Kyereko, according to Business Standard sources. Owusu-Kyereko was promoted to head Jumia Ghana under the loss-cutting reorganization process. Oyolla joins from serving in a similar position at Industrial Promotion Services. His prior work history includes stints at Nokia and Unilever. As always, use protective stops and trade with caution. Good luck to all!
NYSE:JMIALong
by InsiderFinancial
2
$SIG About To Squeeze The Shorts33% of the float in $SIG has been sold short. We are expecting a massive short squeeze to fuel $SIG higher. The latest earnings guidance is the catalyst to do so. Signet Jewelers (NYSE:SIG) reports same store sales were up 1.6% for the two-month holiday period. Same-store sales for the North America business were up 2.0%. E-commerce sales rose 13.5% during the holiday period and brick and mortar same store sales were down 0.2%. Looking ahead, Signet expects FY20 same store sales to rise 0.1% to $6.1B vs. a prior expectation for negative growth. EPS of $3.61 to $3.69 is anticipated vs. $3.26 consensus. For Q4, Signet sees same-store sales growth of 1.1% and EPS of $3.44 to $3.52 vs. $3.11 consensus. CEO update: "We delivered holiday same store sales growth ahead of our guidance as we continued to implement year two of our Path to Brilliance transformation. Product newness, investments in our digital capabilities, and more targeted marketing campaigns drove both eCommerce and brick and mortar growth in North America." As always, trade with caution and use protective stops. Good luck to all!
NYSE:SIGLong
by InsiderFinancial
2
$SDC Climbing As Shorts Cover$SDC is a heavily shorted name with plenty of bears. While we aren't going to get into the bull/bear battle over its business, current price action favors the bulls. We think $SDC can easily squeeze to $18 a share. Currently, 21% of the float has been shorted. Watch yesterday's high of $13.88 for confirmation of going higher. The trade should work out immediately if triggered. As always, use protective stops and trade with caution. Good luck to all!
SLong
by InsiderFinancial
2
$CGC Breaks Out As Expected, More Gains AheadWe said last Thursday that $CGC was on the verge of a breakout and we were right on the money. With 21% of the float short, we expect further short-covering as the shorts get squeezed. We believe the worst is over for $CGC and 2020 is shaping up to be a much better year for cannabis stocks. Also with the US Presidential election coming up, expect some campaign rhetoric about full marijuana legalization. This will further create optimism around the sector. As always, use protective stops and trade with caution. Good luck to all!
CLong
by InsiderFinancial
$CGC On The Verge Of A Breakout$CGC is a cannabis play that keeps getting more interesting by the day. $CGC is the cannabis name to own with $STZ controlling the company and providing downside protection. Bear in mind that $CGC has a $7 billion market cap and $2 billion in cash. This gives $CGC a lot of fire power as we expect further consolidation to take place after last year's bear market. Furthermore, 21% of the float has been sold short. We expect short-covering to start happening and drive $CGC higher. With the stock at $20, our target is $40 and is a stock we are going to take a position in and hold. Canopy Growth Corporation, together with its subsidiaries, engages in engages in production, distribution, and sale of cannabis in Canada. It operates through two segments, Cannabis Operations and Canopy Rivers. The company’s products include dried flowers, oils and concentrates, softgel capsules, and hemps. It offers its products under the Tweed, Spectrum, DNA Genetics, CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Maitri brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada to investigate the efficacy of cannabinoids for the treatment of post-concussion neurological diseases in former NHL players; partnership with Parent Action on Drugs; and a collaboration with Cure Pharmaceutical Holding Corp. for the development of low-dose cannabidiol oral thin films. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada. As always, use protective stops and trade with caution. Good luck to all!
CLong
by InsiderFinancial
10
Is Tesla Powering Down? Fibonacci Says MaybeTesla's been riding one of the most powerful short squeezes in recent history, more than doubling in short order. Its last earnings report in October was the spark because the electric-car maker finally overcame big manufacturing problems. While its popular vehicles were never an issue, logistics and manufacturing were an Achilles heel. Now that they're fixed, bears have been running for cover. But how high can it fly? Some Fibonacci extension lines indicate TSLA might tap the brakes soon. Let's use the latest daily bull flag December 27-31, with a Trend-Based Fib Extension. Going from the bottom to the top of the flag, it projects a target level around $489 based on the 261.8 percent extension. TSLA also began the New Year with small gaps on January 2 and 3. Those might look like exhaustion gaps for some technicians. Finally, the stock is approaching the big round number of $500 which could potentially become psychological resistance. While there is no telling what happens next with a short squeeze like this, traders looking to buy new shares should know about these levels.
NASDAQ:TSLA
by TradeStation
TSLA @ Record hi & Breaking out of next bull flag! Short SqueezeTesla is killing it on execution and deliveries, short interest has gone down from record highs to 20% but $ value has actually grown by $2.3B to a record because shorts are shorting at much higher prices. Longs are sitting on Fat gains and will not sell by end of year. Shorts will cover to offset other huge gains which will cause more shorts to squeeze.Tesla is also releasing FSD preview in "Holiday Update" by end of year (maybe over the weekend), and Tesla will report Record Delivery numbers on Jan 2/3rd. All Indicators are also triggering buy signals... A Perfect storm. This is about to blow up!!!
NASDAQ:TSLALong
by BrandonOsborne
$MNK Looks To Be Turning For The Better$MNK has been badly beaten up over the opioid crisis. It's been a favorite of the shorts and they have banked 77% ytd. However, we think judging by the chart, that $MNK has turned the corner and is set to keep climbing. Shorts can help this climb as 55% of the float has been sold short. We could see a massive short covering rally. The latest news is Mallinckrodt (NYSE:MNK) announces positive findings from a large retrospective study of Acthar Gel in the treatment of the respiratory disease symptomatic sarcoidosis. The company says analysis of a test of 302 patients showed that the use of Acthar Gel was associated with improved overall health status in 95% of patients as reported by physicians' assessments, with more than half of patients (54%) seeing improvements in two or more symptoms. Acthar Gel is approved by the FDA for the treatment of symptomatic sarcoidosis. Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with the Washington University School of Medicine and Silence Therapeutics plc. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom. As always, use protective stops and trade with caution. Good luck to all!
MLong
by InsiderFinancial
2